Dr. Mossé is currently an Assistant Professor of Pediatrics with an independent tenure-track position at the University of Pennsylvania School of Medicine. Dr. Mossé and her team performed a linkage scan in neuroblastoma families, work that led to the identification of germline and somatic mutations in the anaplastic lymphoma kinase gene. Follow-up preclinical studies revealed that ALK mutants show differential sensitivity to ALK inhibition, data that directly impacted the design of the pediatric phase I trial of crizotinib led by Dr. Mossé (ASCO 2012), a rapid translation of preclinical molecular findings into the clinic.

Dr. Mossé has become a key member of a growing team of investigators attempting to streamline the progress of translational genomics, including new drug development. She is an integral member of the neuroblastoma disease committee within the Children’s Oncology Group (COG) and is a member of the neuroblastoma steering committee. This position allows her to integrate the work she does in the laboratory with the work being done in the clinic and to facilitate and streamline the development of rational clinical trials. She has also taken an active role in developmental therapeutics committee within the COG and is currently the Vice Chair of Research for the Phase I Consortium.